J&J's vaccine recommended for emergency use authorization by independent experts. FDA will make a decision this weekend.Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine is one step closer to emergency use authorization (EAU) after an independent panel voted Friday to recommend the U.S. Food and Drug Administration (FDA) issue the EUA.
One of the most important traits investors must have is patience -- the patience to hold shares of great companies through good times and bad times, and even in the face of major market volatility. The companies in question are pharma giant Johnson & Johnson (NYSE: JNJ) and fintech specialist Square (NYSE: SQ). Johnson & Johnson has been grabbing scores of headlines lately thanks to its effort to develop a vaccine for COVID-19.
The healthcare giant is famous for its seminal consumer brands and diverse sources of revenue across virtually every sector of the healthcare industry. Positive data from a vaccine trial, a return to normal for the healthcare system, and the prospect of an exciting new surgical platform could move the conversation away from the company's history toward new sources of growth on the horizon. The U.S. Food and Drug Administration (FDA) recently posted data from a clinical trial saying Johnson & Johnson had met the requirements to obtain emergency use authorization for its COVID-19 vaccine.